• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.

作者信息

Schrock Alexa B, Lai Andrea, Ali Siraj M, Miller Vincent A, Raez Luis E

机构信息

Clinical Development, Foundation Medicine, Inc., Cambridge, Massachusetts.

Biomedical Informatics, Foundation Medicine, Inc., Cambridge, Massachusetts.

出版信息

J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017.

DOI:10.1016/j.jtho.2017.02.017
PMID:28629543
Abstract
摘要

相似文献

1
Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.MET Y1230突变作为MET外显子14跳跃的非小细胞肺癌中克唑替尼耐药的一种获得性机制
J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017.
2
Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.在具有MET外显子14跳跃突变的非小细胞肺癌中，卡博替尼克服克唑替尼对获得性耐药突变MET D1228N的耐药性。
JCO Precis Oncol. 2021 Nov;5:849-853. doi: 10.1200/PO.21.00076.
3
Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.病例报告：MET 外显子 14 跳跃的 NSCLC 中曲妥珠单抗耐药的机制为 HER2 扩增。
Cancer Biol Ther. 2019;20(6):837-842. doi: 10.1080/15384047.2019.1566049. Epub 2019 Feb 11.
4
Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中MET外显子14跳跃导致克唑替尼耐药的获得性机制
J Thorac Oncol. 2019 Jul;14(7):e137-e139. doi: 10.1016/j.jtho.2019.04.021. Epub 2019 May 2.
5
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.非小细胞肺癌中 MET 外显子 14 跳跃导致对克唑替尼获得性耐药。
J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.
6
Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体
J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.
7
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.MET 外显子 14 跳跃型非小细胞肺癌中克唑替尼耐药的预先存在 MET Y1230C 突变的出现
J Thorac Oncol. 2017 Jan;12(1):137-140. doi: 10.1016/j.jtho.2016.09.119. Epub 2016 Sep 22.
8
Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.采用阿法替尼和克唑替尼联合治疗一名患有EGFR突变及伴发MET外显子14跳跃突变的非小细胞肺癌患者并获成功
Clin Lung Cancer. 2019 Jan;20(1):59-62. doi: 10.1016/j.cllc.2018.09.009. Epub 2018 Sep 21.
9
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With Exon 14 Skipping.韩国跳过外显子 14 的非小细胞肺癌患者的特征和临床结局。
In Vivo. 2020 May-Jun;34(3):1399-1406. doi: 10.21873/invivo.11920.
10
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.克唑替尼治疗 MET 外显子 14 突变或 MET 扩增的晚期非小细胞肺癌：一项回顾性、单机构经验。
Oncology. 2022;100(9):467-474. doi: 10.1159/000525188. Epub 2022 Jun 9.

引用本文的文献

1
Tyrosine-Mediated Static and Dynamic Quenching of a Receptor Tyrosine Kinase Biosensor Reveals Inhibitor Binding Modes and Kinase Conformations.酪氨酸介导的受体酪氨酸激酶生物传感器的静态和动态猝灭揭示了抑制剂结合模式和激酶构象。
ACS Chem Biol. 2025 Jul 18;20(7):1683-1695. doi: 10.1021/acschembio.5c00224. Epub 2025 Jun 19.
2
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.在遗传性乳头状肾细胞癌中鉴定出的具有激活型N叶突变的MET变体仍然需要配体刺激。
Mol Oncol. 2025 Feb 20. doi: 10.1002/1878-0261.13806.
3
Targeting c-Met in breast cancer: From mechanisms of chemoresistance to novel therapeutic strategies.
靶向乳腺癌中的c-Met：从化疗耐药机制到新型治疗策略
Curr Res Pharmacol Drug Discov. 2024 Oct 22;7:100204. doi: 10.1016/j.crphar.2024.100204. eCollection 2024.
4
Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and fusion.病例报告：一名非小细胞肺癌伴融合患者因MET Y1230H突变获得对克唑替尼的耐药性。
Front Oncol. 2024 Apr 16;14:1370901. doi: 10.3389/fonc.2024.1370901. eCollection 2024.
5
Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity.筛选超大编码化合物库可导致新的蛋白质-配体相互作用和高选择性。
J Med Chem. 2024 Jan 25;67(2):864-884. doi: 10.1021/acs.jmedchem.3c01861. Epub 2024 Jan 10.
6
Discovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor.发现并优化首个 ATP 竞争型 III 型 c-MET 抑制剂。
J Med Chem. 2023 Jul 13;66(13):8782-8807. doi: 10.1021/acs.jmedchem.3c00401. Epub 2023 Jun 21.
7
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer.SYK 介导的上皮细胞状态与 MET 过表达肺癌中对 c-Met 抑制剂的反应相关。
Signal Transduct Target Ther. 2023 May 15;8(1):185. doi: 10.1038/s41392-023-01403-w.
8
Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.探讨针对肺癌的靶向治疗耐药的靶标机制时 Ba/F3 细胞系统的效用。
Cancer Sci. 2022 Mar;113(3):815-827. doi: 10.1111/cas.15263. Epub 2022 Jan 23.
9
A narrative review of MET inhibitors in non-small cell lung cancer with exon 14 skipping mutations.外显子14跳跃突变的非小细胞肺癌中MET抑制剂的叙述性综述。
Transl Lung Cancer Res. 2021 Mar;10(3):1536-1556. doi: 10.21037/tlcr-20-1113.
10
Narrative review: mesenchymal-epithelial transition inhibitors-meeting their target.叙述性综述：间充质-上皮转化抑制剂——靶向作用
Transl Lung Cancer Res. 2021 Jan;10(1):462-474. doi: 10.21037/tlcr-20-588.